Search Results
Your search for world matches 4350 pages
Showing 2001 - 2050The World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros explore the updated World Health Organization (WHO) classification of nodular lymphocyte-predominant Hodgkin lymphoma. For...
Maximizing Benefit in the Treatment of Immune-Mediated Colitis
Immune-related colitis is the second most common toxicity associated with checkpoint inhibitors, affecting up to 40% of patients. The ASCO Post interviewed Yinghong Wang, MD, PhD, Director of Medication-Induced Colitis and Enteritis, Director of Fecal Microbiota Transplantation, and Associate...
Pivotal Study Reports Positive Findings in Fourth-Line Setting for Advanced GIST
In a late-breaking, oral presentation at the European Society for Medical Oncology (ESMO) 2019 Congress, Margaret von Mehren, MD, presented results from INVICTUS, a pivotal phase III clinical study of ripretinib in patients with advanced gastrointestinal stromal tumor (GIST).1 Ripretinib is an...
Challenging the Global Community to Deliver Equitable Cancer Care for All
For Her Royal Highness Princess Dina Mired of Jordan, ensuring that every patient with cancer receives high-quality care is not an abstract goal—it is personal. Princess Dina saw firsthand the life-and-death differences that access to state-of-the-art oncology care makes in a patient’s life when...
Project Socrates: An Educational Bridge From the FDA to the Public
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Jennifer J. Gao, MD, Acting Associate Director of Education in the OCE, and Richard Pazdur, MD, Director of ...
Boswellia
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, focus on the herbal extract...
Maximizing Benefit in the Treatment of Immune-Mediated Colitis
Immune-related colitis is the second most common toxicity associated with checkpoint inhibitors, affecting up to 40% of patients. The ASCO Post interviewed Yinghong Wang, MD, PhD, Director of Medication-Induced Colitis and Enteritis, Director of Fecal Microbiota Transplantation, and Associate...
Pivotal Phase III Study Evaluates Investigational TKI in Fourth-Line Setting for Advanced GIST
In a late-breaking, oral presentation at the ESMO Congress 2019, Margaret von Mehren, MD, presented results from INVICTUS, a pivotal phase III clinical trial of ripretinib in patients with advanced gastrointestinal stromal tumor (GIST).1 Ripretinib is an investigational tyrosine kinase inhibitor...
Osimertinib Improves Overall Survival vs Gefitinib, Erlotinib in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: FLAURA Phase III Trial
The third-generation tyrosine kinase inhibitor osimertinib extended overall survival compared with the older tyrosine kinase inhibitors gefitinib and erlotinib in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), according to late-breaking final overall survival results of the ...
ESMO Congress 2019 Offers a Global Stage for Important Clinical Data
The European Society for Medical Oncology (ESMO) Congress 2019, held September 27 to October 1 in Barcelona, welcomed clinicians, researchers, journalists, and exhibitors from around the world to hear advances across the oncology spectrum, in both clinical medicine and basic research. For this...
New JCO CCI Article Discusses Difficulties in Gathering Real-World Evidence
A new JCO Clinical Cancer Informatics (JCO CCI) article highlights the challenges in—and need for—obtaining real-world evidence for assessing the effectiveness of precision medicine on areas such as survival, quality of life, cost, and health disparities. The paper, titled “Clinical Molecular...
Cancer.Net: Physician-Generated Content for Patients With Cancer Worldwide
Receiving a cancer diagnosis is a disorienting moment for our patients who are then faced with making difficult decisions regarding their treatment. In order to improve shared decision-making and to increase patient involvement in their care, it is essential to provide patients and their families...
Early Lung Cancer Detection Followed by Minimally Invasive Surgery Saves Lives
Lung cancer remains the number one cancer killer, leading to about 150,000 deaths per year in the United States and accounting for approximately 25% of all cancer deaths in the nation. Early detection has improved survival in other malignancies such as breast, colon, and cervical cancers, but...
Management of Locally Advanced Pancreatic Cancer: A Call for Action
Advances in systemic therapy and supportive care, as well as ongoing improvements in surgical techniques, have led to improved survival for many patients with pancreatic ductal adenocarcinoma. We have observed increased survival with FOLFIRINOX (leucovorin, fluorouracil, irinotecan,...
AACR Project GENIE Begins 5-Year Collaborative Research Project With $36 Million in New Funding
The American Association for Cancer Research (AACR) initiative known as AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE) is launching a 5-year, $36 million research collaboration with a coalition of nine biopharmaceutical companies. The goal of the project is to obtain clinical ...
Remembering Craig Alguire
It is with great sadness that we report Craig Alguire, MD, 42, died on October 11, 2019, at his home in Grand Rapids, Michigan. Diagnosed with grade 4 glioblastoma multiforme in 2015, Dr. Alguire chronicled the effects the cancer was having on his life in his Patient’s Corner column, published in...
Pioneering Breast Surgeon and NSABP Chair, Bernard Fisher, MD, Dies at 101
American physicist and philosopher Thomas Kuhn coined the term “paradigm shift” to connote a fundamental change in the basic concepts and practices of a standard scientific discipline. They are few and far between. To convince the entrenched oncologic surgery community in the 1960s and 1970s that...
Expert Point of View: Mansoor R. Mirza, MD
The time has come to offer all patients a PARP [poly (ADP-ribose) polymerase] inhibitor,” said Mansoor R. Mirza, MD, Chief Oncologist at Copenhagen University Hospital and the invited discussant of the VELIA trial at the ESMO Presidential Symposium. He noted, however, that he wasn’t sure veliparib...
2019 NCRI: CA125 Testing May Help General Practitioners to Detect Ovarian Cancer
Testing for levels of the serum biomarker cancer antigen 125 (CA125) in the blood may be a useful tool for the detection of ovarian cancer, and could help detect other types of cancer among patients in primary care, according to research presented by Funston et al at the 2019 National Cancer...
The Role of Oncologists in Helping Cancer Survivors to Quit Smoking
Several oncology organizations have created guidelines for oncology specialists to help patients with cancer to quit smoking. ASCO has far-reaching goals aimed at tobacco reduction, including cessation tools and other resources. To shed light on the current work in this area, The ASCO Post spoke...
Immunotherapy Combinations Redefine Outcomes for Patients With Advanced Renal Cell Carcinoma
The treatment landscape for patients with advanced renal cell carcinoma has changed drastically over the past several years with the introduction of many new therapeutic options for patients. The revolution began with the U.S. Food and Drug Administration (FDA) approval of nivolumab and ipilimumab...
Machine-Learning Model May Predict Unplanned Hospitalizations After Radiation Therapy for Gastrointestinal Cancer
Unplanned hospitalizations may be common among patients with cancer, but they diminish quality of care while racking up high costs for patients and the health-care system alike. According to data presented at the 2019 ASCO Quality Care Symposium, however, a new predictive model may help providers...
Ravi Thadhani, MD, MPH, Named Chief Academic Officer at Partners HealthCare
Ravi Thadhani, MD, MPH, was named Chief Academic Officer at Partners HealthCare, starting November 11, 2019. Dr. Thadhani most recently served as Vice Dean of Research and Graduate Research Education at Cedars-Sinai Medical Center in Los Angeles. Prior to that, he served as Associate Director of...
2019 Annual Meeting of the American Thyroid Association Briefs
The American Thyroid Association held its 2019 Annual Meeting from October 30 to November 3 in Chicago. Below are brief summaries of important oral presentations on thyroid cancer from the meeting. Incidence and Incidence-Based Mortality in a State Results of a retrospective analysis of thyroid...
Superoxide Dismutase Mimetic for Reducing Severe Oral Mucositis From Concurrent Radiotherapy and Cisplatin in Head and Neck Cancer
In a phase IIb trial reported in the Journal of Clinical Oncology, Anderson et al found that the superoxide dismutase mimetic GC4419 was effective in reducing the duration, incidence, and severity of severe oral mucositis in patients with head and neck cancer receiving concurrent radiotherapy and...
Superoxide Dismutase Mimetic for Reducing Severe Oral Mucositis From Concurrent Radiotherapy and Cisplatin in Head and Neck Cancer
In a phase IIb trial reported in the Journal of Clinical Oncology, Anderson et al found that the superoxide dismutase mimetic GC4419 was effective in reducing duration, incidence, and severity of severe oral mucositis in patients with head and neck cancer receiving concurrent radiotherapy and...
Leave a Legacy of Hope
By including a planned gift to Conquer Cancer ®, the ASCO Foundation, in your estate plans, you can help make a dramatic difference for patients with cancer years into the future. With just one small change to your will or trust, your planned gift of any size will deliver a big impact, and: Your...
ASCO’s Journal of Global Oncology Informs Cancer Care Everywhere
As part of ASCO’s commitment to improving cancer care delivery and outcomes around the world, it publishes the Journal of Global Oncology (JGO). JGO Editorial Board member Lawrence N. Shulman, MD, has been a proponent of global thinking and global action in cancer care throughout his career. Dr....
How Cancer.Net Is Changing to Help Young Adults and Teenagers With Cancer
A diagnosis of cancer always comes as a surprise. Life does not prepare any of us for telling our friends and family that we have cancer, and this can be especially difficult for young adults and teenagers. Cancer interrupts their lives at a time when it is least expected. Life goals,...
Cancer Researcher Mary J.C. Hendrix, PhD, Returns to West Virginia to Lead Her Alma Mater
Nationally regarded melanoma researcher Mary J.C. Hendrix, PhD, was born in La Jolla, California, a seaside community surrounded by ocean bluffs and beaches within the city of San Diego. She was reared in a Navy family that moved from the West Coast to the East Coast during her childhood,...
FLAURA Trial: First-Line Osimertinib Improves Overall Survival in EGFR-Mutated Advanced Lung Cancer
First-line treatment with osimertinib extended overall survival compared with the older tyrosine kinase inhibitors gefitinib and erlotinib in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), according to late-breaking final overall survival results of the phase III FLAURA...
Plasma miR371 Expression as a Biomarker for Active Germ Cell Malignancy
In a study reported in the Journal of Clinical Oncology, Nappi et al showed that plasma microRNA miR371 expression was associated with high specificity and positive predictive values in predicting active germ cell malignancy. Study Details The study included 111 patients with a history of or newly ...
ASCO Breakthrough: Blood-Based Screening Assay With a Novel Multivariate Cancer Risk Score Model
A novel multivariate cancer risk score model demonstrated 60% sensitivity at 98.5% specificity. These findings demonstrate that a blood-based cancer screening assay with a novel risk score model may be a viable method for detecting cancer in asymptomatic individuals, especially in populations at...
Andrew C. von Eschenbach, MD, Honored for Leadership in National Lung Screening Trial
The Prevent Cancer Foundation recently honored Andrew C. von Eschenbach, MD, with the James L. Mulshine, MD, Leadership Award for his work leading the National Lung Screening Trial (NLST), the first large-scale clinical trial for low-dose computed tomography (CT) lung cancer screening. The award...
Cancer Taught Me What It Means to Be a Man
Let’s face it, men don’t go to the doctor as often as we should. At least that has been my experience. I felt compelled to finally make an appointment with my primary care physician after I began working as a research assistant at the Smidt Heart Institute at Cedars-Sinai in 2014, as it felt...
A Tale of Two Eugenes
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Vassiliki Papadimitrakopoulou, MD, Appointed Clinical Development Leader of Pfizer Oncology
Vassiliki Papadimitrakopoulou, MD, has been appointed Clinical Development Leader of Pfizer Oncology. Dr. Papadimitrakopoulou will be based in New York City. Recognized around the world for her expertise in personalized genomics-driven cancer therapies, immunotherapies, translational research, and ...
Engage, Discuss, and Learn With ASCO eLearning Multidisciplinary Molecular Tumor Boards
The ASCO eLearning Multidisciplinary Molecular Tumor Boards (MMTBs) offer participants an opportunity to learn from experts and from each other on a variety of tumor-based topics. MMTB formats alternate between slide-based and discussion forum-based layouts. The discussion-based MMTBs are an...
Studies Report Prolonged Long-Term Survival With Immunotherapy vs Chemotherapy in Advanced NSCLC
Longer-term follow-up of patients with advanced non–small cell lung cancer (NSCLC) who are treated with immunotherapy have appreciably extended survival at 5 years, suggesting that for some patients, this disease can be managed as a chronic condition. These findings are based on two presentations ...
FDA Pipeline: Advances in Prostate Cancer, Urothelial Cancer, Myelofibrosis, and More
In the past few weeks, the U.S. Food and Drug Administration (FDA) has issued regulatory decisions in prostate cancer, urothelial cancer, myelofibrosis, breast cancer, pediatric brain cancer, leukemia, and skin cancer. Breakthrough Therapy Designation for Niraparib in Metastatic...
Selpercatinib: Precision Medicine for RET Fusion–Positive NSCLC
Selpercatinib (LOXO-292), a RET kinase inhibitor, demonstrated antitumor activity in the lungs and brain and durable responses with acceptable tolerability in patients with RET fusion–positive non–small cell lung cancer (NSCLC), according to an updated analysis of the LIBRETTO-001 registration...
Expert Point of View: Myung-Ju Ahn, MD, and Roy Herbst, MD, PhD
Formal discussant Myung-Ju Ahn, MD, of Samsung Medical Center Sungkyunkwan University, Seoul, South Korea, said that the CASPIAN results were similar to those of IMpower133, which found that the addition of the immune checkpoint inhibitor atezolizumab to etoposide/carboplatin significantly...
Durvalumab Plus Chemotherapy: New Option for Extensive-Stage SCLC
The addition of the immune checkpoint inhibitor durvalumab to standard therapy significantly improved overall survival vs standard therapy alone for patients with previously untreated extensive-stage small cell lung cancer (SCLC), according to a preplanned interim analysis of the phase III CASPIAN...
Greater Consensus From Global Experts on Controversies in Prostate Cancer
In late August, experts from around the globe convened in Basel, Switzerland, at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) to discuss controversial areas related to the management of advanced prostate cancer. Although the full proceedings of the conference will be published in...
Novel KRAS Inhibitor Shows Activity in Early Study of Advanced Non–Small Cell Lung Cancer
The investigational KRAS inhibitor AMG 510 yielded clinical activity in patients with advanced non–small cell lung cancer (NSCLC), according to updated results of a small ongoing phase I trial reported at the 2019 International Association for the Study of Lung Cancer (IASLC) World Conference on...
Studies Report Prolonged Long-Term Survival With Immunotherapy vs Chemotherapy in Advanced NSCLC
Longer-term follow-up of patients with advanced non–small cell lung cancer (NSCLC) who are treated with immunotherapy have appreciably extended survival at 5 years, suggesting that for some patients, this disease can be managed as a chronic condition. These findings are based on two presentations ...
ESMO 2019: ASCEND-7: Ceritinib for Patients With ALK-Positive NSCLC Metastatic to the Brain
Patients with ALK-positive non–small cell lung cancer (NSCLC) that was metastatic to the brain at baseline demonstrated whole-body, intracranial, and extracranial responses following treatment with ceritinib, according to findings from the phase II ASCEND-7 study presented by Chow et al at the...
ASCO Announces CancerLinQ Discovery® Research Support Grant Recipients
ASCO has announced the three recipients of its CancerLinQ Discovery® Research Support Grant. The awardees will undertake research projects using data from CancerLinQ Discovery®, an offering of ASCO’s CancerLinQ® initiative that provides deidentified data from patients to academic researchers,...
Raising the Quality of Cancer Care Globally
ASCO’s global vision is, “A world where cancer is prevented or cured, and every survivor is healthy.” In its work toward achieving this vision, the Society offers a robust portfolio of programs that are continually expanding around the world that improve access to quality cancer care, support...
International Innovation Grants Expand Global Reach of Training and Care
Physicians and nurses in low- and middle-income countries (LMICs) have fewer training opportunities, limited medical and educational resources, and insufficient palliative care options for their patients,1 all while these regions are leading the world in new cases of cancer diagnosis.2 An emerging...
